Page 115 - HIV/AIDS Guidelines

regimen: the Retrogene Study. J Infect Dis. 2003;188(7):977-985.

3. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in
heavily pretreated HIV-infected patients. AIDS. 2005;19(15):1643-1647.

4. Jaafar A, Massip P, Sandres-Saune K, et al. HIV therapy after treatment interruption in patients with multiple failure and
more than 200 CD4+ T lymphocyte count. J Med Virol. 2004;74(1):8-15.

5. Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in
patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008;46(2):296-304.
6. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med.
2006;355(22):2283-2296.
7. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected
adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981-1989.
8. DART Trial Team DTT. Fixed duration interruptions are inferior to continuous treatment in African adults starting
therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22(2):237-247.
9. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical
disease progression to AIDS or death. HIV Med. 2007;8(2):96-104.
10. Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on
CD4 T cells: a controlled, prospective trial. AIDS. 2004;18(3):439-446.
11. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for
patients with chronic HIV type 1 infection. Clin Infect Dis. 2005;40(4):594-600.
12. Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on
CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV
Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr. 2005;39(5):523-529.
13. Pogany K, van Valkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell
3
nadir greater than 350 cells/mm : 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J
Acquir Immune Defic Syndr. 2007;44(4):395-400.
14. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune
function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J
Infect Dis. 2007;195(10):1426-1436.
15. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-
AIDS-defining malignancies. AIDS. 2008;22(16):2143-2153.
16. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22(18):2409-
2418.
17. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after
intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child
transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38(3):283-288.
18. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation:
an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42(3):401-407.
19. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult
AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-2400.
20. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the
prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6(10):e1000172.
21. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-
nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an
open-label randomised trial. Lancet. 2007;370(9600):1698-1705.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents H-22

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.